Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance
title

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits

 

escrs app advert yo advert

Posters

Search Title by author or title

Preoperative subpterygium Avastin and mitomycin C injection: clinical and histological study

Poster Details

First Author: A. Hasan EGYPT

Co Author(s):    M. Abozed                    

Abstract Details

Purpose:

to detect the clinical and histological effect of preoperative subpterygium injection of both Bivacizumab(Avastin) and Mitomycin C (MMC ) one month before primary pterygium surgical excision with bare scleral technique.

Setting:

Sohag Faculty Of Medicine, Egypt

Methods:

20 patients with primary pterygium underwent subpterygium injection of 0.1 mL of MMC (0.2 mg/mL) with 0.1 mL of Avastin (1.25mg0.1ml ) 1 month before pterygium excision, and 2 patients served as controls without preoperative injection. The excised specimens of pterygium were examined histologically and patients were followed up for two years clinically.

Results:

no intraoperative complications with no actual recurrence occurred in the follow up period. Histologically the Epithelial cells of the treated pterygium decreased in number, stromal fibroblasts were decreased in number, were rounded or ovale swllen rather than spindle-shaped,; some were degenerating or apoptotic. Collagen and elastic fibers were degenerated ,less density and distorted .obliteration of capillaries .

Conclusions:

clinically subpterygium injection of Avastin and MMC is safe and effective procedure in reducing the recurrence of primary pterygium after surgery Histologically changes occurred in pterygium tissue after injection of Avastin and MMC in the form of decrease fibrovascular activity , degeneration of the extracellular matrix and nerve axons. These changes matched with clinical observation of reduced vascularity in the pterygium after Avastin and MMC injection.

Financial Disclosure:

NONE

Back to Poster listing